Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.76 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938429 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL528531 | 0.85 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938989 | 0.83 | HDAC3 (0.87) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL7936301 | 0.82 | HDAC3 (0.73) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL7935007 | 0.79 | HDAC3 (0.69) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1937664 | 0.78 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938042 | 0.76 | HDAC3 (0.80) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938227 | 0.76 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938335 | 0.75 | HDAC3 (0.78) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1937940 | 0.75 | HDAC3 (0.74) | HDAC3HDAC1NCOR2HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885NCOR2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.